Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
51 studies found for:    Open Studies | "Gastrointestinal Stromal Tumors"
Show Display Options
Rank Status Study
21 Recruiting Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Conditions: Gastrointestinal Stromal Tumors (GIST);   Other Relapsed or Refractory Solid Tumors
Intervention: Drug: BLU-285
22 Recruiting Ph II CABOGIST in GIST
Condition: Metastatic Gastrointestinal Stromal Tumor
Intervention: Drug: cabozantinib
23 Recruiting Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
Condition: Gastrointestinal Stromal Tumour (GIST)
Intervention: Drug: regorafenib
24 Recruiting Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs
Condition: Gastrointestinal Stromal Tumors (GISTs)
Intervention: Drug: Regorafenib
25 Recruiting A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
Condition: Gastrointestinal Stromal Tumors (GISTs)
Intervention: Drug: Imatinib Mesylate
26 Not yet recruiting Efficacy of Ferric Carboxymaltose in Patients With Gastrointestinal Stromal Tumor (GIST) Receiving Systemic Therapy
Conditions: Malignant Neoplasms of Mesothelial and Soft Tissue;   Gastrointestinal Stromal Tumor With Neurogenic Differentiation
Interventions: Drug: Ferric Carboxymaltose;   Dietary Supplement: Iron Supplements;   Behavioral: Questionnaire
27 Recruiting A Retrospective Pharmacokinetics and Pharmacogenomics Research of Imatinib in Gastrointestinal Stromal Tumor Treatment
Conditions: Gastrointestinal Stromal Tumors;   Germline Mutation;   Somatic Mutation;   Plasma Concentration
Intervention:
28 Recruiting Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib Therapy
Condition: Gastrointestinal Stromal Tumor
Intervention:
29 Not yet recruiting MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: 68Ga-NeoBOMB1, 2-vial kit
30 Recruiting Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: regorafenib
31 Recruiting Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: imatinib
32 Recruiting The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib
Conditions: Colorectal Neoplasms;   Gastrointestinal Stromal Tumors
Interventions: Drug: Esomeprazole 40mg concomitantly;   Drug: Esomeprazole 40mg before;   Drug: Regorafenib 160mg or 120mg
33 Recruiting Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
Conditions: Gastrointestinal Stromal Tumors;   Resected Gastrointestinal Stromal Tumors;   Non-metastatic;   High Risk of Recurrence;   KIT Gene Mutation
Intervention: Drug: Imatinib maintenance
34 Not yet recruiting Long Outcome of Endoscopic Submucosal Dissection for Small Gastrointestinal Stromal Tumors (<2cm)
Condition: GIST
Intervention: Procedure: ESD
35 Recruiting Treatment Response Evaluation in Gastrointestinal Stromal Tumor (GIST) Patients
Conditions: Soft Tissue Neoplasms;   Gastrointestinal Tract
Intervention:
36 Recruiting Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor
Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Gastrointestinal Stromal Tumor;   Premenopausal
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Procedure: Ultrasonography
37 Recruiting Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
Conditions: Carcinoma, Renal Cell, Advanced;   Lymphoma, Mantle-Cell;   Gastrointestinal Stroma Tumors
Interventions: Drug: Temsirolimus;   Drug: Sunitinib;   Drug: Axitinib
38 Recruiting A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
Conditions: Neoplasms, Nerve Tissue;   Neurofibromatosis 1;   Heredodegenerative Disorders, Nervous System;   Peripheral Nervous System Diseases
Intervention: Drug: Selumetinib (AZD6244 hyd sulfate)
39 Recruiting Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
Condition: Gastric Cancers
Intervention:
40 Recruiting Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST
Condition: GIST With D842V Mutated PDGFRA Gene
Interventions: Drug: Crenolanib;   Drug: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-51) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.